多发性骨髓瘤患者对BNT162b2 mRNA新冠疫苗的体液应答率及预测因素
这项单中心前瞻性研究纳入171例多发性骨髓瘤(MM)患者,在第二剂BNT162b2疫苗接种后14-21天检测血清学应答。冒烟型骨髓瘤患者为100%(822 U/ml)。多因素分析显示高龄、暴露于≥4种新型抗骨髓瘤药物及低丙种球蛋白血症与较低应答率相关。
要点
- 活动性MM患者接种BNT162b2后血清阳性率76%,低于健康对照的98%。
- 高龄、≥4种新型抗骨髓瘤药物暴露及低丙种球蛋白血症与较低应答率相关。
- 疫苗不良事件多为短暂1-2级,MM患者与对照发生率分别为53%和55%。
核心结论
- BNT162b2疫苗在MM患者中安全并提供高血清阳性率,且不依赖治疗类型。
- 高龄、低丙种球蛋白血症及重度预处理患者应答率较低。
研究设计与样本
- 单中心前瞻性研究,纳入171例MM患者(159例活动性MM,12例冒烟型骨髓瘤),中位年龄70岁(38-94)。
- 以64名已接种疫苗的健康志愿者为对照。
- 第二剂疫苗接种后14-21天检测血清学应答。
主要发现
- 冒烟型骨髓瘤患者血清阳性率为100%(中位滴度822 U/ml)。
- 不良事件在MM患者和对照中分别占53%和55%,均为短暂1-2级。
关键数值与推荐
- 冒烟型骨髓瘤血清阳性率100%(中位滴度822 U/ml)。
临床怎么用
- MM患者接种BNT162b2疫苗安全,可提供较高血清阳性率,支持在该人群中接种。
- 对高龄、低丙种球蛋白血症及重度预处理患者应关注应答可能较低,考虑加强监测或额外防护。
局限性
- 单中心研究,样本量有限。
- 仅评估血清学应答,未报告临床突破感染或细胞免疫应答数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) patients are at excess risk for clinically significant COVID19 infection. BNT162b2 mRNA COVID19 (BNT162b2) vaccine provides effective protection against COVID19 for the general population, yet its effect in MM patients may be compromised due to disease and therapy-related factors and was not yet evaluated. This single-centre prospective study included MM patients tested for serological response 14-21 days post second vaccine. Vaccinated healthy volunteers served as controls. In all, 171 MM patients, median age 70 (38-94) were included; 159 active MM and 12 smouldering myeloma (SMM). Seropositive response rate (median titer) was 76% (91 U/ml) in active MM patients vs 98% (992 U/ml) in the 64 controls (P < 0·0001), and 100% (822 U/ml) in SMM patients. Multivariate analysis revealed older age (P = 0·009), exposure to ≥4 novel anti-myeloma drugs (P = 0·02) and hypogammaglobulinaemia (P = 0·002) were associated with lower response rates. None of the novel agents significantly decreased response rate, whereas daratumumab trended towards reduced response (P = 0·08). Adverse events occurred in 53% and 55% of the MM patients and controls, respectively, all transient grade 1-2. In conclusion, BNT162b2 vaccine was safe and provided a high seropositivity rate in MM patients, independent of treatment type. Older, hypogammaglobulinaemic and heavily pretreated patients had lower response rates.
引用
- Avivi I, Balaban R, Shragai T, et al. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. Br J Haematol. 2021. PMID: 34196388. doi:10.1111/bjh.17608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。